|
Biogen earnings hurt by Tysabri
LOS ANGELES April 28, 2005 - the withdrawal of its Tysabri multiple
sclerosis treatment the market had an adverse impact on Biogen Idec's
earnings, the company said Wednesday.
After the markets closed Wednesday, Biogen (BIIB) reported net income of
$43.5 million, or 12 cents a share, for the period ended March 31. A year
ago, the company reported a loss of $41.2 million, or 12 cents a share.
Revenue for the Cambridge, Mass., company was $587.8 million vs. last year's
$541.7 million.
Excluding charges, the company earned 30 cents a share. Analysts polled by
Thomson First Call expected the company to report earnings of 37 cents a
share, an estimate that excludes charges.
Click here for full article.
|
|
